Generic biologics: A comparative analysis of regulatory review

BioProcess International

Volumn 9, Issue 8, 2011, Pages 34-40

  Konski, Antoinette F ^a  

^a FOLEY AND LARDNER LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGIC; ERYTHROPOIETIN; GENERIC DRUG; GROWTH HORMONE; INSULIN; INTERFERON; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANEMIA; CHINA; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG APPROVAL; DRUG COST; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; INDIA; MULTIPLE SCLEROSIS; REVIEW;

EID: 80053197790     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (16)

1. The Patient Protection and Affordable Care Act. Pub. L. No. 11-148, 124 Stat. 119 (2010), as amended by the Health Care and Education Reconciliation Act of 2010. Pub. L. No. 111-152, 124 Stat. 1029 (2010).
2. Miller S, Houts J. Potential Savings of Biogenerics in the United States. Express Scripts February 2007; www.express-scripts.com/research/studies/ pharmacybenefitresearch/specialtypharmacyservices/docs/ potentialSavingsBiogenericsUS.pdf.
3. Biotechnology Industry Organization. A Follow-On Biologics Regime Without Strong Data Exclusivity Will Stifle the Development of New Medicines. www.bio.org/healthcare/followonbkg/FOBSMarket-exclusivity-20070926.pdf.
4. Kaldre I. The Future of Generic Biologics: Should the United States "Follow-On" the European Pathway? Duke Law and Technology Review 2008; www.law.duke.edu/journals/dltr/articles/2008dltr0009.html.
5. Schellekens H. How Similar to "Biosimilars" Need to Be? Nature Biotech. 22 2004: 1357-1358.
6. EMEA Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products. 30 October 2005.
7. Guise JW, Carson BM. Biogeneric Regulatory Policies in China and India: A Comparison Study. Drug Information Journal 44, 2010: 55-57.
8. Wright Bonilla JD, Beaver NA. New Legal Pathway for Biosimilar Creates Opportunities and Challenges for Biological Manufacturers: A Guide to the Legislation. Bloomberg Law Reports 3(6) 2010.
9. Gottlieb S. Biosimilars: Policy, Clinical, and Regulatory Considerations. Am. J. Health-Sys. Pharm. 65(6) 15 July 2008.
10. Nowicki M. Basic Facts About Biosimilars. Kidney Blood Press Res. 30, 2007: 267-272. (Pubitemid 47482057)
11. Rosen D, Lian L. The US Biosimilar Regulatory Scheme and Comparison with the European Experience: Where Do We Go from Here? Pharmaceutical Technology Sourcing and Management 7(3); pharmtech.findpharma.com/pharmtech/Formulation/ Next-Steps-for-the-US-Biosimilar-Regulatory-Scheme/ArticleStandard/Article/ detail/711302).
12. Concept Paper on the Revision of the Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substances: Quality Issues. 7 February 2011; www.ema.europa.eu/ema/index.jsp? curl=/pages/home/Home-Page.jsp&jsenabled=true.
13. Personal communication. Sky Xiaomin patent attorney, Scihead Patent Agent Co. Ltd., Guangdong, PR China.
14. Biosimilars Seen as a $3.7 Billion Drug Market by 2015. Reuters 29 March 2011; www.reuters.com/article/2011/03/28/pharmaceuticals-biosimilar.
15. Merck Buys Hanwha's Drug-Marketing Rights. 14 June 2011, WSJ on-line; http://online.wsj.com/article/SB10001424052702303714704576383063665947924.html.
16. Dealtalk: Race to Copy Biotech Drugs Creates Odd Bedfellows. Reuters 19 July 2011; www.reuters.com/article/2011/06/22/us-pharmaceuticals-biotech- idUSTRE75L2M020110622.